LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of an abstract for poster presentation at the CHEST 2024 Annual Meeting, taking place October 6-9 in Boston. The Company is also sponsoring an Industry Symposium at the meeting.

宾夕法尼亚州兰霍恩市——（商业新闻短讯）——萨瓦拉公司（Nasdaq:SVRA）（该公司）是一家专注于罕见呼吸道疾病的临床阶段生物制药公司，于10月6日至9日在波士顿举行的2024年胸部年会上宣布接受一份摘要，用于海报展示。该公司还在会上主办了一场行业研讨会。

Details are as follows:.

详情如下：。

Accepted Abstract

接受摘要

Title: “A Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)”

标题：“自身免疫性肺泡蛋白沉着症（aPAP）患者的旅程图”

Poster Session: Diffuse Lung Disease Abstracts Posters (D)

海报会议：弥漫性肺病摘要海报（D）

Date and Time: October 8, 2024, 1:45 - 2:30pm EDT

日期和时间：美国东部时间2024年10月8日下午1:45 h2:30

Company-Sponsored Symposium

公司主办的研讨会

Title: “Pulmonary Alveolar Proteinosis: Pathophysiology, Diagnosis, and Management”

标题：“肺泡蛋白沉着症：病理生理学，诊断和管理”

Location: CHEST Learning Theater

Date and Time: October 8, 2024, 2:00 - 2:45pm EDT

日期和时间：美国东部时间2024年10月8日下午2:00 2:45

Speaker: Ali Ataya, M.D., Associate Professor of Medicine, University of Florida, Division of Pulmonary and Critical Care Medicine

演讲者：Ali Ataya，医学博士，佛罗里达大学肺部和重症监护医学系医学副教授

About aPAP

关于aPAP

Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli (or air sacs) of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages.

自身免疫性PAP是一种罕见的肺部疾病，其特征是肺泡（或气囊）中表面活性剂异常积聚。表面活性剂由蛋白质和脂质组成，是一种重要的生理物质，排列在肺泡上以防止其塌陷。在健康的肺中，过量的表面活性剂被称为肺泡巨噬细胞的免疫细胞清除和消化。

Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas exchange, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue.

肺泡巨噬细胞需要被粒细胞巨噬细胞集落刺激因子（GM-CSF）刺激才能正确清除表面活性剂，但在自身免疫性PAP中，GM-CSF被抗GM-CSF的抗体中和，使巨噬细胞无法充分清除表面活性剂。结果，过量的表面活性剂积聚在肺泡中，导致气体交换受损，导致呼吸急促的临床症状，通常伴有咳嗽和频繁疲劳。

Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long-term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant..

。从长远来看，这种疾病可能导致严重的并发症，包括肺纤维化和需要进行肺移植。。

About Savara

关于萨瓦拉

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH).

Savara是一家临床阶段的生物制药公司，专注于罕见的呼吸道疾病。我们的主要项目molgramostim吸入溶液是一种吸入性粒细胞巨噬细胞集落刺激因子（GM-CSF），处于自身免疫性肺泡蛋白沉着症（aPAP）的3期发展中。Molgramostim通过研究性eFlow®雾化器系统（PARI Pharma GmbH）提供。

Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)..

我们的管理团队在罕见呼吸系统疾病和肺部医学方面拥有丰富的经验，能够识别未满足的需求，并有效地推动候选产品获得批准和商业化。更多信息可以在www.savarapharma.com上找到。（X，以前称为推特：@savarapharma，LinkedIn:www.LinkedIn.com/company/savara pharmaceuticals/）。。